Skip to main content
Premium Trial:

Request an Annual Quote

Celera, Abbott To Seek Genetic Markers of Response to Abbott Compound

NEW YORK (GenomeWeb News) – Celera and Abbott are collaborating on a project to identify genetic markers for an undisclosed investigational compound under development at Abbott, Celera said today.
The partners plan to determine whether genetic variants Celera has identified can predict how patients may respond to treatment with the drug.
Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform the study. Any companion diagnostic product resulting from the study could be developed by Celera and commercialized through its ongoing alliance with Abbott.
“The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy,” said Thomas White, chief scientific officer at Celera, in a statement. “Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.